AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-4 RER
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Study NCT05253495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NAVD-R, Cycle 1-2
Description: brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Study NCT05253495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Site Radiation Therapy
Description: 21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
Study NCT05573230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT05573230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05573230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered orally.
Study NCT05726032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Study NCT05726032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Study NCT05418829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-007
Description: AT-007 20 mg/kg once daily
Study NCT06400940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
Description: Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
Study NCT06400940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
Description: Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
Study NCT04192019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro-glucagon
Description: Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
Study NCT04192019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini-glucagon
Description: Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
Study NCT05746364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating
Description: The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
Study NCT04831710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab,200mg, ivd, d1
Study NCT04831710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide,30mg,po,biw,d1-21
Study NCT05880901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school program
Description: The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.
Study NCT05880901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer day camp
Description: The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
Study NCT05438628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Measurement of thickness of rectus abdominis, biceps brachii muscles
Study NCT06571565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
Study NCT05827848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation system
Description: All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
Study NCT06571565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
Study NCT06201104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient empowerment education
Description: After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients.
Study NCT05031767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.
Study NCT05031767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital .
Study NCT05031767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-initiated care
Description: No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.
Study NCT04937790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization group(CSG)
Description: Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
Study NCT04937790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wobble board group (WBG)
Description: Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
Study NCT06340282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Immersive virtual reality
Study NCT06340282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent exercise
Description: individualized exercise
Study NCT06306131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 0.15 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Study NCT06306131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam 15 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Study NCT06306131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate 750 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Study NCT05033431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
Study NCT05388799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
Study NCT05090254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment algorithms targeting cardiac output
Description: Treatment algorithms targeting maximization or personalization of cardiac output
Study NCT05232227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine double dose over 14 days
Description: Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
Study NCT05232227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine single dose over 14 days
Description: Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
Study NCT00546026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placental function assessment
Description: Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-208
Description: PO, Once daily(QD), 24weeks
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2081
Description: PO, Once daily(QD), 24weeks
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of AD-208
Description: PO, Once daily(QD), 24weeks
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of AD-208
Description: PO, Once daily(QD), 24weeks
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of AD-2081
Description: PO, Once daily(QD), 24weeks
Study NCT04825561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of AD-2081
Description: PO, Once daily(QD), 24weeks
Study NCT05206097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
Study NCT06082479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoral cryotherapy,ice gel
Description: A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
Study NCT05620524 — intervention group
Intervention type: DRUG
Intervention: Extra blood samples for determining exposure to 5-FU
Description: Extra blood samples for determining exposure to 5-FU
Study NCT04794257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring of the recurrent laryngeal nerves
Description: The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
Study NCT04794257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromonitoring of the recurrent laryngeal nerves
Description: The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
Study NCT03962400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning
Description: New computer based procedure for determining dose using a decision support tool
Study NCT03962400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heath Care Provider
Description: Warfarin dose will be determined by a qualified health care provider
Study NCT05063994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Over-encapsulated hydrocortisone modified-release capsules for oral administration - 5mg and 10mg
Study NCT05063994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: Over-encapsulated immediate-release hydrocortisone capsules for oral administration - 5mg and 20mg
Study NCT05348252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Journey App
Description: The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
Study NCT05348252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information folder
Description: The group will receive all information and instructions on discontinuing PPI use through an information folder.
Study NCT04895501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running flexible shoes
Description: 21kms of running flexible shoes followed by a time-to-exhaustion run.
Study NCT04895501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: running flexible shoes
Description: 21kms of running flexible shoes followed by a time-to-exhaustion run.
Study NCT05728476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy combined with ILM peeling
Description: Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.